Publication of Clinical Results: ⁹⁹ᵐTc-maraciclatide Demonstrates Excellent Potential as a Whole-Body Imaging Method for Rheumatoid Arthritis

  • Serac Life Sciences
  • October 22, 2025
  • Edited 1 month ago

Serac Healthcare  announces that the findings from a Phase II study evaluating a novel molecular imaging agent, 99mTc-maraciclatide, as an imaging marker for rheumatoid arthritis (RA) have been published online in Academic Radiology.

Read more
Share this article with a friend

Create an account to access this functionality.
Discover the advantages

Create account